an increase of 34.6%

Editor's Note: plates of traditional Chinese medicine 22.99% for the first three quarters of sales growth in revenue, higher than the overall 21.05% of the pharmaceutical sector growth. Current domestic listed companies typically have multiple base of traditional Chinese medicine drug or health insurance as well as exclusive species, niche concentration of relatively strong and established through the brand strength or means of protection of traditional Chinese medicineHigh barrier to gain a better long-term development environment. At the same time due to the characteristics of traditional Chinese medicine, in the areas of cardiovascular medicine, anticancer drugs, Chinese medicine can give full play to its role in target, market size and prospects are very substantial. 　　In addition, in the field of cosmetic and health products, some enterprises will face of inflection points of profit opportunities. Medicine prices enterprise profitsRun recovery by the medicinal plant resources of traditional Chinese medicine, medicinal mineral medicinal animals and three parts, about 11,118 species of medicinal plants, natural medicine raw material suppliers, mainly to China, India and Brazil. The World Bank reported that the 2000 natural drugs industry in the world around US $ 80 billion, 2010 up to $ 200 billion, international natural medicine marketField is rapidly expanding. The first half of 2011, domestic enterprises of proprietary Chinese medicines prevalent phenomenon of rising operating costs, pientzehuang (600,436), Guangzhou pharmaceutical (600,332), Hong margin pharmacy (600,557), Jilin aodong (000623) and Chinese medicine Jiang (600,750), operating costs increase revenue increase by more than10%. Beginning in July, relevant departments of the national drug stockpile increase the intensity of combat, while production of proprietary Chinese medicine Enterprise reduce the stock, coupled with the herbalist broadening the scope of planting, breeding, herbs this year a large number of listed factors prompted the Chinese medicinal material prices began to fall. By October 2011, Chengdu fell 13.55% price means the highest point of Chinese medicinal materials, prices of Chinese medicinal materialsRose finally reversed the trend for many years in a row, will enable enterprises of Chinese herbal medicines as the main raw material before heavy cost pressures have eased. For manufacturers of proprietary Chinese medicines, and grasp the quality from the source is the first priority of the protection of Chinese traditional medicine production. Proprietary Chinese medicine enterprises with upstream resource dependencies, building GAP base is best for achieving sustainable development of enterprise wayDiameter, higher level of organization on a large scale, "contract farming" or widely promoted in the future. By the end of 2010, more than a total of more than 50 enterprises of Chinese medicinal materials in China, 72 base 52 species through the GAP of Chinese medicinal materials certification. Tasly in listed companies (600,535), Tong ren Tang (600,085), 39 pharmaceutical companies such as was earlier a group ofStart planning and GAP of Chinese medicinal materials planting proprietary Chinese medicines manufacturers. Proprietary Chinese medicine profits continue to improve yield in September 2011 tons of proprietary Chinese medicines in China, an increase of 51.32% production since 2007 and has been on an upward trend, 2011-September yield growth rates are higher than the 40% of traditional Chinese medicine, well ahead of last yearThe growth rate. At the same time the first three quarters of traditional Chinese medicine companies operating income grew by 23.55%, operating profit grew by 33.27%, mayinglong (600,993), Yi-Bai pharmaceuticals (600,594), tasly, ConMed pharmaceutical industry (600,518), Kunming pharmaceutical (600,422), pientzehuang and Dong-e e-Jiao (000423)Good corporate earnings. Chinese herbal medicine and proprietary Chinese medicine both sub-sectors are growing faster, 2011-September proprietary Chinese medicines revenues $ 172.9 billion, an increase of 34.6%, totalling 17 billion yuan in profits, an increase of 28.4%. January-September of prepared traditional Chinese medicines industry revenues of $ 41.6 billion yuan, an increase of 53%, itGross profit 31.7%, an increase of 56.4%. 　　Herbal industry revenue, gross profit and gross margin per cent growth rate than traditional Chinese medicine industry, mainly by the price of Chinese medicinal materials prices, profits due to redistribution in the industry. Injections from traditional Chinese medicine industry market expanded under the guidance of injections from traditional Chinese medicine refers to the theory of traditional Chinese medicine, the use of modern technology, from the skySo made available for extraction of active substance in the drug into the body of sterile preparations. Injections may generally be divided into solution injection, powder for injection, injection with suspension and emulsion for injection and so on. Injections from traditional Chinese medicine in traditional Chinese medicine, is the original new forms. It has high bioavailability, quickly, without gastrointestinal absorption, nor hepatic first-pass effect, to overcome theLack of effect of traditional Chinese medicine to slow, while both traditional Chinese medicine fuzheng quxie, clearing, the advantages of promoting blood circulation and removing blood stasis swtor credits, enhance the body immunity. Compound growth rate of 30% injections from traditional Chinese medicine market in recent years, higher than the average growth rate in medical industry. Statistics show that in nine cities in 2010 amount of proprietary Chinese medicines, injections formulations accounted for less than the maximum, exceeding the capsules, tabletsCommission form, around 35.47%. Injections from traditional Chinese medicine widely used in cardiac and cerebral vascular disease, tumor diseases, respiratory diseases, musculoskeletal system diseases and diseases of the digestive system of the five major disease areas, played a good therapeutic effect. Cardio-cerebral-vascular areas account for less than the maximum, to 59.71%, while in the field of anti-tumor and the area of the respiratory system,Drug injection are the star product. In 2011, Polyphenolic acids of Salvia miltiorrhiza injection of tasly company approved, this variety was the first since 2008 was granted a variety of injections from traditional Chinese medicine, is expected to go on sale this year. Polyphenolic acids of Salvia miltiorrhiza injection approved, marking the traditional Chinese medicine injection approval Gates opened again, policy loosening is expected to bring quickly to industryExhibition of new opportunities. New forms of injections from traditional Chinese medicine is our original, is the exploration of the future international pharmaceutical industry marketing one of the unique advantages of the project, there is great market demand. 　　On the international markets, particularly Germany and other European countries, technology manufacture and clinical use of plant drug injection has been widely recognized. Derivatives are icing on the cake of traditional Chinese medicine of traditional Chinese medicine derivedProduct is based on a traditional Chinese medicine, the use of specific attributes of traditional Chinese medicine, different demands for consumer, health care and preservation elements and organic combination of daily life a group of products, covering all aspects of people's lives. Current markets for this product has great potential, attract many enterprises, especially enterprises joining in traditional medicine, in just a few years time, the derivative market of traditional Chinese medicine have begun to take shape, Today mainly concentrated in traditional Chinese medicine, Chinese medicine and health products, and other fields. Daily chemical means of traditional Chinese medicine pharmaceutical enterprise based on the principle of traditional Chinese medicine, combining elements of traditional Chinese medicine and daily chemical products, pharmaceutical, health care, cosmetic products, when multiple properties. With the inflow of imported cosmetic, some domestic companies started looking for cosmetic development road with Chinese characteristics, a number of pharmaceutical companies involved in skin careProducts, such as tongrentang, pientzehuang enterprises entering the health care market segments of traditional Chinese medicine, launched a series of skin care products. As the disposable income of urban residents and growing spending power, daily chemical industry, pharmaceutical enterprises across the territories of more powerful market segments of traditional Chinese medicine subject matter, themes of traditional Chinese medicine product market share increase year by year, showing the tremendous potential of the domestic market. According to first half 2010Year, Yunnan baiyao (000538) toothpaste market share amounted to 10%, become a national brand of toothpaste. At present the Ministry of health health food is 22 kinds of admissibility, including the regulation of immune and regulating blood lipid, regulation of blood sugar, such as regulating blood pressure, anti-aging. In addition, there is resistance to oxidation, improve microcirculation, blocking the synthesis of n-nitroso compounds, raiseWhite blood cell and caries in teeth, beauty in the abundance of milk, and so on. One such blood products of traditional Chinese medicine has always been the choice for consumers, Dong-e e-Jiao products are consumers of the product. Pientzehuang is China's top secret prescription drugs, but due to the natural musk pientzehuang recipes belong to resource depletion of raw materials, product is in short supply. By 2012 our health productsMarket sales will reach $ 120 billion, a potentially huge market is expected to become channels for enterprises to speed up the growth of traditional medicine. Attention circulation equity securities stock pool securities code name (billion) net assets per share ($) third-quarter earnings per share (Yuan) shares highlights 600,436 pientzehuang 1.4 cent1.381 high-end consumer demand, into the cosmetic and health products market 600,535 tasly 4.88 6.81 benefited from primary health care marketing and application development, Dan-Shen root dropping pill in the pace of Yunnan baiyao 6.29 7.5 000538 baiyao steady growth, The two wings of products focused on commodity market of traditional Chinese medicine 000423 Dong-e e-Jiao 6.54 deep blood market, diversification strategies prompted value regression 300,026 Sun pharmaceuticals (300,026) both 0.54 6.13 antithrombotic drugs production and marketing, North market monopoly